Protalix BioTherapeutics Sets New 1-Year Low at $3.61 (PLX)
Protalix BioTherapeutics (NYSE:PLX) hit a new 52-week low on Monday , Analyst Ratings News reports. The company traded as low as $3.61 and last traded at $3.64, with a volume of 97,523 shares. The stock had previously closed at $3.77.
Several analysts have recently commented on the stock. Analysts at JPMorgan Chase & Co. cut their price target on shares of Protalix BioTherapeutics from $8.00 to $7.00 in a research note on Tuesday, May 13th. They now have an “overweight” rating on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of Protalix BioTherapeutics in a research note on Monday, May 12th. They now have a $4.25 price target on the stock, down previously from $5.50. Finally, analysts at Zacks downgraded shares of Protalix BioTherapeutics from a “neutral” rating to an “underperform” rating in a research note on Wednesday, April 9th. They now have a $4.30 price target on the stock.
The stock’s 50-day moving average is $3.85 and its 200-day moving average is $4.30. The company’s market cap is $338.3 million.
Protalix BioTherapeutics (NYSE:PLX) last announced its earnings results on Thursday, May 22nd. The company reported ($0.08) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.07) by $0.01. On average, analysts predict that Protalix BioTherapeutics will post $-0.22 earnings per share for the current fiscal year.
Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.